ALX ONCOLOGY HOLDINGS INC 8-K

What Happened

• ALX Oncology Holdings Inc. filed an 8-K on June 11, 2026 reporting the voting results from its Annual Meeting held June 10, 2026. Three Class II director nominees — Daniel Curran, M.D.; Rekha Hemrajani; and Chris Takimoto, M.D., Ph.D. — were elected to serve until the 2029 annual meeting.
• Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers (say-on-pay) and ratified the appointment of KPMG LLP as the company’s independent registered public accounting firm for the 2026 fiscal year.

Key Details

• Director election vote totals:
  • Daniel Curran, M.D.: For 100,933,233; Withheld 57,798; Broker non-votes 18,313,833.
  • Rekha Hemrajani: For 82,732,430; Withheld 18,258,601; Broker non-votes 18,313,833.
  • Chris Takimoto, M.D., Ph.D.: For 100,946,696; Withheld 44,335; Broker non-votes 18,313,833.
• Advisory vote on executive compensation: For 84,540,061; Against 13,497,711; Abstain 2,953,259; Broker non-votes 18,313,833.
• Ratification of independent auditor (KPMG LLP): For 119,293,775; Against 1,797; Abstain 9,292.

Why It Matters

• Board continuity: The election of all three nominees maintains the current board composition through the 2029 annual meeting, which affects governance and oversight of ALX Oncology.
• Governance signal: Shareholder approval of the advisory say-on-pay indicates a majority vote in favor of the company’s executive compensation disclosures and practices as presented in the proxy.
• Audit continuity: Ratifying KPMG LLP ensures continuity of the company’s independent audit arrangements for fiscal 2026, a routine but important governance matter for investors.